Abstract
Introduction: Metastatic disease (M+) at diagnosis is the most important negative prognostic clinical marker in medulloblastoma (MB) patients and despite the use of craniospinal irradiation and chemotherapy is one of the leading causes of treatment failure. Few parameters have been evaluated to obtain a prognostic profile for these high-risk patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
